Navigation Links
Sun Pharmaceutical Extends Tender Offer for Taro
Date:9/3/2008

MUMBAI, India, Sept. 3 /PRNewswire/ -- Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUN PHARMA, BSE: 524715) today announced its subsidiary, Alkaloida Chemical Company Exclusive Group Ltd. (Alkaloida), has extended the Expiration Date of the Tender Offer for the purchase of all outstanding Ordinary Shares of Taro Pharmaceutical Industries Ltd. (Taro). The Offer will now expire at 5:00 p.m., New York City time, on Friday, October 3, 2008, unless further extended or earlier terminated. The Tender Offer was extended to comply with an order issued by the Supreme Court of Israel temporarily prohibiting the closing of the Offer until the Supreme Court issues a decision on the appeal of the litigation commenced against Alkaloida and its affiliates by Taro and certain of its directors regarding the applicability of the special tender offer rules under the Israeli Companies Law to the Offer. The Tel-Aviv District Court had previously ruled in favor of Sun Pharma that a special tender offer was not required.

The Supreme Court's order states that the appeal will be heard no later than December 15, 2008, but no briefing schedule has yet been set. If the temporary order remains in effect and the Supreme Court has not decided the appeal by October 3, 2008, Sun will further extend the Offer while the temporary order remains outstanding.

The Offer was commenced on June 30, 2008 in order to comply with the terms of the Option Agreement between Alkaloida and the controlling shareholders of Taro. Alkaloida exercised its options to acquire shares of Taro from the controlling shareholders on June 25, 2008. The Option Agreement required Alkaloida, promptly after exercising the options, to commence a tender offer at USD 7.75 per Ordinary Share of Taro held by other shareholders. The Offer had previously been scheduled to expire at 5:00 p.m., New York City time, on Wednesday, September 3, 2008. As of 5:00 p.m., New York City time, on Se
'/>"/>

SOURCE Sun Pharmaceutical Industries Ltd.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Safecor Health Acquires Unit-Dose Pharmaceutical Leader RSC
2. Osprey Pharmaceuticals U.S.A., Inc. Completes $11 Million Initial Private Financing
3. Peregrine Pharmaceuticals to Report First Quarter FY 2009 Financial Results
4. OncoGenex Pharmaceuticals announces out-license of TOCOSOL Paclitaxel to Eagle Pharmaceuticals
5. Amylin Pharmaceuticals to Present at Thomas Weisel Healthcare, BioCentury NewsMakers, and Morgan Stanley Global Healthcare Conferences
6. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
7. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the 2008 NewsMakers In the Biotech Industry Conference
8. Trubion Pharmaceuticals to Present at Fall 2008 Morgan Stanley Global Healthcare Unplugged Conference in New York
9. Alexza Pharmaceuticals Announces Upcoming Webcasts and Conference Participation
10. Poniard Pharmaceuticals Announces Upcoming Conference Participation
11. Amylin Pharmaceuticals and Eli Lilly Provide Context for FDA Alert for BYETTA

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2009)...ewswire-Asia/ -- WuXi PharmaTech (NYSE: WX ), a,...-device research and,development outsourcing compa...,announced that it had been selected to the Deloit...h consecutive year. The list recognizes the 50,fas...a, and telecommunications,industries based on reve...
(Date:11/29/2009)... , The concept of confinement is one of the ce...mple is that of quarks which bind together to form...elmholtz-Zentrum Berlin together with an internati...an experimental realization and a proof of confine...tem. , The concept of confinement states that in...
(Date:11/27/2009)...ire-FirstCall/ -- Stallergenes has been,granted Eu...s and children,through a Mutual Recognition Proced...as been marketed, was the reference Member state. ..., Belgium, Bulgaria, Cyprus, the,Czech Republic, E... Italy,Latvia, Lithuania, Luxembourg, Malta, the ...
(Date:11/25/2009)...Newswire/ -- Research Triangle Park-based Cnanoz I...eatment water purification system NanoPure(TM) dev...nister of Rural Water Supply, Hon. Minister Viswar...itial tests, performed at Indian Institute of Tech...f the drinking water available in India contains t...
Breaking Biology Technology:WuXi PharmaTech Named in Deloitte Technology Fast 50 China 2009 List for the Fifth Consecutive Year 2Spinons -- confined like quarks 2STALLERGENES is Granted a Marketing Authorization for Oralair(R) in Europe 2STALLERGENES is Granted a Marketing Authorization for Oralair(R) in Europe 3North Carolina-based Cnanoz Unveils NanoPure(TM) to Government Leaders in Hyderabad, India 2
...aGen to receive approximately $45 million in cash,...ne payments - - Provides updated financ...o be hosted today at 9:00 a.m. EDT -, BRANFORD, C... ), a clinical-stage biopharmaceutical company, an...linostat, a Phase I/II histone,deacetylase inhibit...
...LLE, Calif., April 21 Ortho Evra is an adhesive,t...release 150 mcg of,norelgestromin and 20 mcg of et... It is replaced once a week for three weeks, and n... was approved by the FDA in November,2001, and ove...pproval.,Ortho Evra continues to be marketed aggre...
... Million Net Revenues, $0.03 Net Loss Per Share, ...logies, Inc. (Nasdaq: VNUS ), a leading provider ...tment of venous disease, today announced its,finan... 2008., Net revenues for the first quarter of 200....6 million for the first quarter of 2007. As,expec...
Other Biology Technology:CuraGen Sells Ownership of Belinostat to TopoTarget A/S 2CuraGen Sells Ownership of Belinostat to TopoTarget A/S 3CuraGen Sells Ownership of Belinostat to TopoTarget A/S 4CuraGen Sells Ownership of Belinostat to TopoTarget A/S 5Ortho Evra Patch Makers Settling Cases 2VNUS Medical Technologies Reports First-Quarter 2008 Results: 21% growth in Net Revenues and 51% Growth in Unit Sales 2VNUS Medical Technologies Reports First-Quarter 2008 Results: 21% growth in Net Revenues and 51% Growth in Unit Sales 3VNUS Medical Technologies Reports First-Quarter 2008 Results: 21% growth in Net Revenues and 51% Growth in Unit Sales 4VNUS Medical Technologies Reports First-Quarter 2008 Results: 21% growth in Net Revenues and 51% Growth in Unit Sales 5VNUS Medical Technologies Reports First-Quarter 2008 Results: 21% growth in Net Revenues and 51% Growth in Unit Sales 6VNUS Medical Technologies Reports First-Quarter 2008 Results: 21% growth in Net Revenues and 51% Growth in Unit Sales 7
(Date:11/30/2009)..., New Orleans, LA Researchers from LSU Health Sc... Eunice Kennedy Shriver National Institute of Chil...hool of Public Health, Brigham and Women,s Hospita...first time that drinking more than 5 servings of s...ears to significantly elevate the risk of developi...
(Date:11/30/2009)..., Two so-called invasion proteins are crucial for...surface of human cells, which stimulates the host ...ptor molecules exert a different function, for exa...ng. The group,s results have now been published in...iology ". , Spoiled meat is one of the sources f...
(Date:11/30/2009)..., If you ever thought the stress of seeing your e...g youbad news: a new research report in the Decemb...iology ( http://www.jleukbio.org ) shows that you...m the same study might lead to entirely new treatm..., arthritis, and eczema under control. That,s beca...
Breaking Biology News(10 mins):Sugary cola drinks linked for first time to higher risk of gestational diabetes 2Sugary cola drinks linked for first time to higher risk of gestational diabetes 3It takes 2 to infect 2Seeing family for the holidays? Scientists discover how the stress might kill you 2UCR scientists manipulate ripples in graphene enabling strain based graphene electronics 13195 1UCR scientists manipulate ripples in graphene enabling strain based graphene electronics 13195 2UCR scientists manipulate ripples in graphene enabling strain based graphene electronics 13195 3Surgery remans an option for advanced lung cancer 52719 1Surgery remans an option for advanced lung cancer 52719 2Common allergy drug reduces obesity and diabetes in mice 9359 1Common allergy drug reduces obesity and diabetes in mice 9359 2Common allergy drug reduces obesity and diabetes in mice 9359 3Common allergy drug reduces obesity and diabetes in mice 9359 4
...rcent of women rely on their healthcare providers ...ercent said their doctor has talked to them about ...avirus (HPV) - according to a new survey released ...onals (ARHP). HPV is extremely common, affecting a...n their lifetime, in some cases staying dormant un...
...r manipulating macromolecules has been developed b...ana-Champaign. The technique uses double-stranded ...In previous DNA nanotechnology efforts, duplex DNA...ometrical objects in three dimensions. Instead of ...rchers are using DNA to control the folding and re...
...r manipulating macromolecules has been developed b...ana-Champaign. The technique uses double-stranded ...In previous DNA nanotechnology efforts, duplex DNA...ometrical objects in three dimensions. Instead of ...rchers are using DNA to control the folding and re...
Other Biology News:Survey reveals women and doctors aren't talking about HPV 2Survey reveals women and doctors aren't talking about HPV 3Health costs soar as 60 million Americans classed as obese 2UN successfully tests 'green' pesticide against locusts 2
Human Mesenchymal Stem Cell Functional Identification Kit from R&D Systems
Goat Anti-Human Carnosine Dipeptidase 1 Polyclonal Antibody, Unconjugated from R&D Systems
Rabbit Anti-Syntrophin alpha 1 Polyclonal Antibody, Unconjugated from Abcam
Mouse Anti-VEGF Receptor 1 Monoclonal Antibody, Unconjugated, Clone Flt-1 / EWC from Abcam
Biology Products: